Cargando…

Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin

In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-densit...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Ji Soo, Kim, Kyu, Jung, Youngae, Lee, Jae-Hwan, Namgung, June, Lee, Hae-Young, Suh, Jon, Hwang, Geum-Sook, Lee, Sang-Hak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168550/
https://www.ncbi.nlm.nih.gov/pubmed/30279504
http://dx.doi.org/10.1038/s41598-018-33058-x
_version_ 1783360372292452352
author Han, Ji Soo
Kim, Kyu
Jung, Youngae
Lee, Jae-Hwan
Namgung, June
Lee, Hae-Young
Suh, Jon
Hwang, Geum-Sook
Lee, Sang-Hak
author_facet Han, Ji Soo
Kim, Kyu
Jung, Youngae
Lee, Jae-Hwan
Namgung, June
Lee, Hae-Young
Suh, Jon
Hwang, Geum-Sook
Lee, Sang-Hak
author_sort Han, Ji Soo
collection PubMed
description In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-density lipoprotein-cholesterol targets, but had triglyceride and high-density lipoprotein-cholesterol levels ≥150 mg/dL and <50 mg/dL, respectively, were randomized to receive atorvastatin 20 mg or atorvastatin 10 mg/fenofibric acid 135 mg for 12 weeks. Metabolite profiling of serum was performed and changes in metabolites after drug treatment in the two groups were compared. Analysis was performed using patients’ samples obtained before and after treatment. Of 89 screened patients, 37 who met the inclusion criteria were randomized, and 34 completed the study. Unlike that in the dose-escalation group, distinct clustering of both lipid and aqueous metabolites was observed in the combination group after treatment. Most lipid metabolites of acylglycerols and many of ceramides decreased, while many of sphingomyelins increased in the combination group. Atorvastatin dose escalation modestly decreased lysophosphatidylcholines; however, the effect of combination therapy was variable. Most aqueous metabolites decreased, while l-carnitine remarkably increased in the combination group. In conclusion, the atorvastatin/fenofibric acid combination induced distinct metabolite clustering. Our results provide comprehensive information regarding metabolic changes beyond conventional lipid profiles for this combination therapy.
format Online
Article
Text
id pubmed-6168550
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61685502018-10-05 Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin Han, Ji Soo Kim, Kyu Jung, Youngae Lee, Jae-Hwan Namgung, June Lee, Hae-Young Suh, Jon Hwang, Geum-Sook Lee, Sang-Hak Sci Rep Article In the current study, the metabolic effects of atorvastatin dose escalation versus atorvastatin/fenofibric acid combination were compared using metabolomics analyses. Men and women with combined hyperlipidaemia were initially prescribed atorvastatin (10 mg, ≥4 weeks). Patients who reached low-density lipoprotein-cholesterol targets, but had triglyceride and high-density lipoprotein-cholesterol levels ≥150 mg/dL and <50 mg/dL, respectively, were randomized to receive atorvastatin 20 mg or atorvastatin 10 mg/fenofibric acid 135 mg for 12 weeks. Metabolite profiling of serum was performed and changes in metabolites after drug treatment in the two groups were compared. Analysis was performed using patients’ samples obtained before and after treatment. Of 89 screened patients, 37 who met the inclusion criteria were randomized, and 34 completed the study. Unlike that in the dose-escalation group, distinct clustering of both lipid and aqueous metabolites was observed in the combination group after treatment. Most lipid metabolites of acylglycerols and many of ceramides decreased, while many of sphingomyelins increased in the combination group. Atorvastatin dose escalation modestly decreased lysophosphatidylcholines; however, the effect of combination therapy was variable. Most aqueous metabolites decreased, while l-carnitine remarkably increased in the combination group. In conclusion, the atorvastatin/fenofibric acid combination induced distinct metabolite clustering. Our results provide comprehensive information regarding metabolic changes beyond conventional lipid profiles for this combination therapy. Nature Publishing Group UK 2018-10-02 /pmc/articles/PMC6168550/ /pubmed/30279504 http://dx.doi.org/10.1038/s41598-018-33058-x Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Han, Ji Soo
Kim, Kyu
Jung, Youngae
Lee, Jae-Hwan
Namgung, June
Lee, Hae-Young
Suh, Jon
Hwang, Geum-Sook
Lee, Sang-Hak
Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title_full Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title_fullStr Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title_full_unstemmed Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title_short Metabolic Alterations Associated with Atorvastatin/Fenofibric Acid Combination in Patients with Atherogenic Dyslipidaemia: A Randomized Trial for Comparison with Escalated-Dose Atorvastatin
title_sort metabolic alterations associated with atorvastatin/fenofibric acid combination in patients with atherogenic dyslipidaemia: a randomized trial for comparison with escalated-dose atorvastatin
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168550/
https://www.ncbi.nlm.nih.gov/pubmed/30279504
http://dx.doi.org/10.1038/s41598-018-33058-x
work_keys_str_mv AT hanjisoo metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT kimkyu metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT jungyoungae metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT leejaehwan metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT namgungjune metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT leehaeyoung metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT suhjon metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT hwanggeumsook metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin
AT leesanghak metabolicalterationsassociatedwithatorvastatinfenofibricacidcombinationinpatientswithatherogenicdyslipidaemiaarandomizedtrialforcomparisonwithescalateddoseatorvastatin